Systematic literature reviews include non-achievement of pCR, residual cancer burden, and fewer tumour-infiltrating lymphocytes (TILs), as risk factors specifically identified for early-stage HER2-positive BC recurrence [23]. Here, ERBB2 is linked to neoplasm.